HGEN News and Press, Humanigen Inc. From 03/09/20

Coronavirus triggers cytokine storm in infected patients resulting in severe lung damage and death Lenzilumab is in clinical studies for prevention of cytokine storm BURLINGAME, CA / ACCESSWIRE / March 9, 2020 / Humanigen, Inc., (OTCQB:HGEN) ("Humanigen"), a clinical stage bio...

BURLINGAME, CA / ACCESSWIRE / December 16, 2019 / Humanigen, Inc., (OTCQB:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on the development of next-generation CAR-T and other cell therapies, announced today that Cheryl Buxton, Korn Ferry's Global Sector Leader of Pha...

Improved survival demonstrated with GM-CSF knockout CAR-T GM-CSF knockout CAR-T results in altered gene transcriptome with decreased death receptors including Fas Presentation received an ASH Abstract Achievement Award BURLINGAME, CA / ACCESSWIRE / December 11, 2019 / Hum...

BURLINGAME, CA / ACCESSWIRE / December 2, 2019 / Humanigen, Inc., ( OTCQB: HGEN ) ("Humanigen"), a clinical stage biopharmaceutical company focused on the development of next generation CAR-T and other cell therapies, announced today that it is has terminated the process of exploring a po...

Noteworthy events during the week of November 17 - 23 for healthcare investors. More news on: Resverlogix Corp., Surface Oncology, Inc., Humanigen, Inc., Healthcare stocks news, , Read more ...

BURLINGAME, CA / ACCESSWIRE / November 15, 2019 / Humanigen, Inc., (OTCQB:HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on the development of next generation chimeric antigen receptor T cell (CAR-T) and other cell therapies, today announced that Dr. Cameron Durran...

EphA3 is a novel CAR-T tumor target expressed in tumor neovasculature and stroma Phase I study of ifabotuzumab (anti-EphA3 antibody) resulted in rapid, specific and reproducible targeting of the tumor microenvironment (TME) and tumor vasculature in patients with glioblastoma multiforme...

Improved survival demonstrated with GM-CSF knockout CAR-T Study demonstrates that activated CAR-T cells upregulate and signal through GM-CSF receptors GM-CSF knockout CAR-T results in altered gene transcriptome with decreased expression of Fas BURLINGAME, CA / ACCESSWIRE / ...

Humanigen ( OTCQB:HGEN ) plans to conduct a broadly syndicated rights offering involving issuing a dividend of rights and over-subscription rights to purchase shares of its capital stock (“Shares”). More news on: Humanigen, Inc., Healthcare stocks news, Read m...

BURLINGAME, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on the development of next generation CAR-T and other cell therapies, announced today that it is contemplating conducting a br...